MRNA (Moderna) Inventories, Finished Goods : $28 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Moderna Inventories, Finished Goods?

Moderna's quarterly finished goods increased from Jun. 2024 ($34 Mil) to Sep. 2024 ($146 Mil) but then declined from Sep. 2024 ($146 Mil) to Dec. 2024 ($28 Mil).

Moderna's annual finished goods declined from Dec. 2022 ($169 Mil) to Dec. 2023 ($24 Mil) but then increased from Dec. 2023 ($24 Mil) to Dec. 2024 ($28 Mil).

Moderna Inventories, Finished Goods Historical Data

The historical data trend for Moderna's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Inventories, Finished Goods Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Finished Goods

Get a 7-Day Free Trial

1.00

233.00

169.00

24.00

28.00

Moderna Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventories, Finished Goods	Get a 7-Day Free Trial															24.00	20.00	34.00	146.00	28.00

Moderna Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Moderna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

MRNA:Peru MRNA:Mexico 1MRNA:Italy 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

325 Binney Street, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Executives

Stephane Bancel	director, officer: Chief Executive Officer	320 BENT STREET, CAMBRIDGE MA 02141
Shannon Thyme Klinger	officer: Chief Legal Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Stephen Hoge	officer: President	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock	officer: Chief Financial Officer	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay	officer: Chief Commercial Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Juan Andres	officer: See Remarks	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline	officer: Chief Financial Officer	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez	officer: See Remarks	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan	director	AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson	officer: General Counsel and Secretary	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115